Publication | Open Access
Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients
23
Citations
19
References
2022
Year
RheumatologyOcular DiseaseLower Relapses RateOphthalmologyOcular PathologyMulticenter StudyMedicineInfliximab Versus Adalimumab
| Year | Citations | |
|---|---|---|
Page 1
Page 1